By the time this Editorial is published, I will have retired after more than nine years as Head of the European Centre for the Validation of Alternative Methods (ECVAM), and returned from Italy to England, to devote as much as possible of my remaining years to my voluntary role as Chairman of the Trustees of the Fund for the Replacement of Animals in Medical Experiments (FRAME). This is not the place to review in detail what has been achieved at ECVAM since 1993, especially as the Proceedings of the ECVAM Status Seminar, held at Ispra on 4-6 June 2002, will be published as a supplement to ATLA, later this year. In addition, a report on Alternative (Non-animal) Methods for Chemicals Testing: Current Status and Future Prospects, prepared by ECVAM and the ECVAM Working Group on Chemicals, is being published as a supplement to accompany this issue of ATLA. 1 However, because the knives appear to be out already -I have heard rumours from various quarters that certain people are lamenting that little has been achieved by ECVAM since 1993, as "only three methods have been validated" -I thought that it would be appropriate to take this opportunity to briefly summarise what we have achieved.
As was pointed out last year, 2 ECVAM's principal responsibility in the test development, validation and acceptance sequence ends when the ECVAM Scientific Advisory Committee (ESAC) makes or endorses a public statement about the scientific validity or status of a test method or a proposed action. As Table 1 shows, the ESAC has so far made or endorsed 16 statements, ten concerning chemicals and six concerning biologicals (vaccines, antibodies, sera and hormones). Other studies currently in progress will lead to further statements, of course, but, in four particular areas, events in which ECVAM has been involved have progressed to the point where statements will shortly be made. These concern the scientifically validated GM-CFU in vitro test for acute neutropenia, in vitro methods for the potency testing of recombinant follicle-stimulating hormone, in vitro testing for percutaneous absorption, and the replacement of the LD50 test by three in vivo methods which require fewer animals and cause less animal suffering.
ATLA 30, 261-262, 2002 261 Editorial Alternatives to Animal Experiments: "Goodbye ECVAM, Hello FRAME" Some formal steps still remain for these TGs for alternative methods, but they are now well on the way to acceptance at the OECD level, and therefore to worldwide application. This was the first time that a consortium of animal welfare organisations (ICAPO) had participated in such an OECD meeting. It is reported that their presence and interventions were welcomed by the official delegates, and that they raised the question of the three in vitro tests for embryotoxicity, recently endorsed as scientifically valid by the ESAC.
Only those who are aware of OECD procedures, and have been involved in the protracted discussions which have led to these recent successes, will be able to fully appreciate their significance and realise how grateful those committed to alternatives should be to all concerned (and, not least, to Herman Koëter and his colleagues in the OECD Secretariat, of whom I may have appeared to be critical in the past . . . ).
However, this is not a time to be complacent, for significant though these steps may be, they are small in relation to the length and difficulty of the journey on which we have embarked. The EU Chemicals Policy and demands for tests for socalled endocrine disruptors are merely two examples of the many challenges that we face.
I look forward to working with my colleagues in FRAME, with my former colleagues at ECVAM, and with our network of collaborators in industry, academia and government, to contribute to the development and validation of alternative methods, and to the improvement of the regulatory process, so that chemicals and products of various kinds, including medicines, vaccines, medical devices, cosmetics, household products and agricultural products, can be manufactured, transported and used more economically and more safely, while the current reliance on animal test procedures is progressively reduced. 
